Oncogenic Role of KIF18B Across Human Cancers: A Pan-Cancer Bioinformatic Analysis and Experimental Validation in Lung Adenocarcinoma
Frontiers in Bioscience-Landmark · 2026
DOI: 10.31083/fbl47910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Junli Hou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, 225000 Yangzhou, Jiangsu, …. Hauptthemen laut MEDLINE: Kinesins, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2024 Yangzhou Basic Research Program (Joint Special Projects).
Abstract (Originalsprache)
Background
Identifying oncogenic drivers with broad relevance across multiple cancer types is critical for developing novel therapeutic strategies. Kinesin family member 18B (KIF18B) is involved in mitotic regulation, but its comprehensive role and clinical significance across human malignancies remain poorly understood. This study performed a comprehensive pan-cancer analysis of KIF18B and experimentally validated its role in lung adenocarcinoma (LUAD).
Methods
We conducted a comprehensive bioinformatic analysis using public databases to evaluate the expression profile, prognostic value, and potential biological functions of KIF18B across various human cancers. Based on these findings, LUAD was selected for further investigation. We evaluated KIF18B protein levels in LUAD cell lines (A549, HCC827, H1975) and compared them to a normal bronchial epithelial cell line (BEAS-2B). Subsequently, KIF18B was silenced in A549 cells using small interfering RNA (siRNA), and its effects on cell proliferation, migration, and invasion were examined using colony formation, wound-healing, and Transwell assays.
Results
Our analysis across various cancers revealed that KIF18B is markedly overexpressed, including in LUAD, and this high expression correlates with poor prognosis in patients across different cancer types. In line with these bioinformatic results, our experiments confirmed that KIF18B protein levels were elevated in LUAD cell lines compared with normal controls. Functional assays demonstrated that knockdown of KIF18B in A549 cells significantly suppressed colony-forming ability and impaired migratory and invasive capacities.
Conclusions
This study, integrating pan-cancer bioinformatic analysis with experimental validation, establishes KIF18B as a widely expressed oncogene with significant prognostic value. Our findings in LUAD confirm its crucial role in promoting key malignant phenotypes. Thus, KIF18B emerges as a valuable prognostic biomarker and a potential therapeutic target, not only for LUAD but potentially for a wider array of cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Yangzhou University, Yangzhou University, 225000 Yangzhou, Jiangsu, China.
Förderung
- 2024 Yangzhou Basic Research Program (Joint Special Projects)
Zitieren
APA
Hou, J., Shao, X., Zhang, Y., Jin, F., Xu, W., & Xu, X. (2026). Oncogenic Role of KIF18B Across Human Cancers: A Pan-Cancer Bioinformatic Analysis and Experimental Validation in Lung Adenocarcinoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl47910
Vancouver
Hou J, Shao X, Zhang Y, Jin F, Xu W, Xu X. Oncogenic Role of KIF18B Across Human Cancers: A Pan-Cancer Bioinformatic Analysis and Experimental Validation in Lung Adenocarcinoma. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl47910
BibTeX
@article{Hou2026,
author = {Hou, Junli and Shao, Xiangrong and Zhang, Yawen and Jin, Feng and Xu, Wenwen and Xu, Xiantao},
title = {Oncogenic Role of KIF18B Across Human Cancers: A Pan-Cancer Bioinformatic Analysis and Experimental Validation in Lung Adenocarcinoma},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
doi = {10.31083/fbl47910}
}
EUVIMED